I begge studier blev baseline- demografiske og sygdomsrelaterede karakteristika sammenlignet mellem lenalidomid/ dexamethason- og placebo/ dexamethason- grupperne.
In both studies, the baseline demographic and disease-related characteristics were comparable between the lenalidomide/dexamethasone and placebo/dexamethasone groups.